Please assess the completion status of the following clinical trial:

Trial Title: Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of oligoarticular, polyarticular, psoriatic or enthesitis-related JIA as determined by ILAR criteria. Patients who have been continuously treated with generic sulfasalazine delayed release formulation and have tolerated the product for at least 3 months prior to study enrolment and who are switched to Azulfidine-EN at least 8 days prior to Day 0 are eligible.~* Patients must be at least 6 years of age and has not reached his/her 18th birthday prior to the Baseline Visit (Day 0).~* Onset of JIA must have occurred prior to the patient's 16th birthday.~* Patients must weigh at least 20 kg.~* Patients must be on sulfasalazine 500 mg delayed release tablets and the total daily dose must be within the specified range of 30-60 mg/kg/day with a maximum daily dose of 3 g/day~Exclusion Criteria:~* Patient currently with systemic features of systemic JIA.~* Hypersensitivity to sulfasalazine , its metabolites, sulfonamides or salicylates.~* History of sensitivity to heparin or heparin-induced thrombocytopenia.~* Inability to swallow whole (uncrushed) sulfasalazine 500 mg delayed release tablets as required by protocol

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 6 days

Based on this trial design, predict the completion outcome and termination type (if applicable).